What does WuXi XDC Cayman do?

WuXi XDC helps drug companies discover, develop and manufacture antibody drug conjugates (ADCs), which are targeted medicines that link an antibody to a potent drug payload, often used against cancer. It makes both the active ingredients and the finished drug products, as well as the antibody and payload-linker components that go into them. It serves clients in China, North America, Europe and elsewhere.

What is WuXi XDC Cayman's fair value?

On an owner-earnings DCF, WuXi XDC Cayman's most-likely fair value is about HK$29, versus a recent price near HK$84. A margin-of-safety estimate, not a price target. Analysis, not advice.

Healthcare · Diagnostics & Research · 2268.HK

What WuXi XDC Cayman Does & How It Makes Money (2268.HK)

Updated October 2026 · reflects WuXi XDC Cayman's latest reported financials

Contract developer and manufacturer of antibody drug conjugates and bioconjugates. It earns fees from pharmaceutical and biotech clients for contract research, development and manufacturing of bioconjugate drug substances and drug products, plus international sales contracting services.

WuXi XDC Cayman's story, moat and numbers — in a 3-minute visual book.

Explore WuXi XDC Cayman on TacticScale →

How WuXi XDC Cayman makes money

It earns fees from pharmaceutical and biotech clients for contract research, development and manufacturing of bioconjugate drug substances and drug products, plus international sales contracting services.

What WuXi XDC Cayman does

WuXi XDC Cayman Inc. is a contract research, development and manufacturing organization (CRDMO) specializing in antibody drug conjugates and other bioconjugates. It covers the full chain from discovery and process development to manufacturing of drug substances and drug products, including monoclonal antibody intermediates and payload-linkers, for clients in China, North America, Europe and other markets. Founded in 2013 and headquartered in Wuxi, China, the company is a subsidiary of WuXi Biologics (Cayman) Inc. It also engages in anti-tumor drug R&D, manufacturing and marketing, provides international sales contracting services, and has strategic collaborations with Earendil Labs and Akari Therapeutics.

Products & services

Antibody drug conjugate (ADC) CRDMO services
Bioconjugate drug substance and drug product manufacturing
Monoclonal antibody intermediates
Payload-linker development and manufacturing
International sales contracting services

What is WuXi XDC Cayman worth?

On an owner-earnings DCF, WuXi XDC Cayman's most-likely value is about HK$29 versus a recent price near HK$84 (194% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~HK$9) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Verdict: Fairly priced — no edge

Owner-earnings fair value · recent price ≈ HK$84

Fair value (most likely)

HK$29

Range

HK$16–HK$60

No-growth floor

HK$9

Price

~HK$84

Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.

Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →

Sector Healthcare Industry Diagnostics & Research HQ China Ticker 2268.HK Official site

Related companies

WuXi Biologics (2269.HK) · WuXi AppTec (603259.SS) · Xencor (XNCR)

Understand WuXi XDC Cayman in 3 minutes →